(MENAFN- GlobeNewsWire - Nasdaq) – Single subcutaneous dose of ADX-038 achieved near-complete alternative pathway suppression for 6 months, supporting potent and selective CFB silencing – – Phase 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback